Pathogenesis and prevention of graft-versus-host disease

Current Opinion in Organ Transplantation

Volumn 6, Issue 3, 2001, Pages 265-271

  Teshima, Takanori ^a   Ferrara, James L M ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOSPORIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GANCICLOVIR; INTERLEUKIN 11; KERATINOCYTE GROWTH FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; TRIPTOLIDE; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; CELL INTERACTION; CHIMERA; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE SEVERITY; DONOR; GRAFT VERSUS HOST REACTION; HOST; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INHIBITION KINETICS; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0035700105     PISSN: 10872418     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075200-200109000-00012     Document Type: Article

References (86)

1. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry
2. Pathogenesis of acute graft-versus-host disease: Cytokines and cellular effectors
3. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease
4. Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier
5. Induction of monocyte- and T-cell-attracting chemokines in the lung during the generation of idiopathic pneumonia syndrome following allogeneic murine bone marrow transplantation
6. Prevention of graft versus host disease by inactivation of host antigen-presenting cells
7. CTLA-4 and T cell activation
8. Monoclonal antibody and receptor antagonist therapy for GVHD
9. Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice
10. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice
11. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease
12. IL-15 and IL-2: A matter of life and death for T cells in vivo
13. Prolonged secretion of IL-15 in patients with severe forms of acute graft-versus-host disease after allogeneic bone marrow transplantation in children
14. IL-12 is a central mediator of acute graft-versus-host disease in mice
15. Regulation of interferon-gamma production by IL-12 and IL-18
16. Role of natural killer cells in the development of graft-versus-host disease
17. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets
18. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease
19. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease
20. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12
21. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice
22. IL-18 prevents the development of chronic graft-versus-host disease in mice
23. Differentiation of T regulatory cells by immature dendritic cells
24. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells
25. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy
26. Adoptively transferred gamma delta T cells indirectly regulate murine graft-versus-host reactivity following donor leukocyte infusion therapy in mice
27. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation
28. Neutralization of tumor necrosis factor-alpha action delays but does not prevent lung injury induced by alloreactive T helper 1 cells
29. Hyporesponsiveness of donor cells to lipopolysaccharide stimulation reduces the severity of experimental idiopathic pneumonia syndrome: Potential role for a gut-lung axis of inflammation
30. Bacterial translocation during graft-versus-host disease after small bowel transplantation is reduced following inhibition of inducible nitric oxide synthesis
31. Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: Release of intracellular iron and nitric oxide-mediated cytostasis
32. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation
33. Differential effects of anti-Fas ligand and anti-tumor necrosis factor-α antibodies on acute graft-versus-host disease pathologies
34. Fas ligand-deficient gld mice are more susceptible to graft-versus-host-disease
35. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia
36. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity
37. Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity
38. Pathways of T-cell regeneration in mice and humans: Implications for bone marrow transplantation and immunotherapy
39. Immunological reconstitution following bone marrow transplantation
40. The effect of graft-versus-host disease on T cell production and homeostasis
41. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells
42. Progress in graft-versus-host disease
43. Massive activation-induced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft-versus-host disease
44. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function
45. New strategies for bone marrow transplantation
46. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance
47. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment
48. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation
49. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation
50. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice
51. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease
52. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation
53. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury
54. KGF pretreatment decreases B7 and granzyme B expression and hastens repair in lungs of mice after allogeneic BMT
55. Interactions of keratinocyte growth factor with a nitrating species after marrow transplantation in mice
56. Cyclophosphamide prevents systemic keratinocyte growth factor-induced up-regulation of surfactant protein A after allogeneic transplant in mice
57. Rapamune (sirolimus, rapamycin): An overview and mechanism of action
58. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome
59. Graft-versus-host disease prevention by rapamycin: Cellular mechanisms
60. p27kip1 functions as an energy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes
61. T cell clonal anergy
62. Interleukin-2-mediated elimination of the p27Kip 1 cyclin-dependent kinase inhibitor prevented by rapamycin
63. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation
64. PG27, an extract of Tripterygium wilfordii hook f, induces antigen-specific tolerance in bone marrow transplantation in mice
65. Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion
66. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice
67. Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-non-identical marrow transplant model
68. Blockade of CTLA-4 signals inhibits Th2-mediated murine chronic graft-versus-host disease by an enhanced expansion of regulatory CD8+ T cells
69. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibit murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells
70. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease
71. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation
72. Sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease
73. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation
74. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator
75. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response
76. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway
77. Transplantation of anergic histoincompatible bone marrow allografts
78. CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses
79. Analysis of the requirements for the induction of CD4+ T cell alloantigen hyporesponsiveness by ex vivo anti-CD40 ligand antibody
80. Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta
81. Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-beta-treated alloreactive T cells that do not induce graft-versus-host disease
82. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice
83. Induction of oral tolerance in splenocyte recipients toward pretransplant antigens ameliorates chronic graft versus host disease in a murine model
84. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation
85. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients
86. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease